민정준 (전남대학교 의과대학) | 한빛사논문 > 한빛사

한빛사논문

조회312

전남대학교 의과대학

CV File 777 kb

Nat. Rev. Clin. Oncol., Jun 05 2024, | https://doi.org/10.1038/s41571-024-00908-9 Exploiting bacteria for cancer immunotherapy

Seong-Young Kwon ^1,2, Hien Thi-Thu Ngo ^1,3,4, Jinbae Son ⁵, Yeongjin Hong ^1,5,6,7 & Jung-Joon Min ^{1,2,3,5,6,7,*}

¹Institute for Molecular Imaging and Theranostics, Chonnam National University Medical School, Jeonnam, Republic of Korea.
²Department of Nuclear Medicine, Chonnam National University Medical School and Hwasun Hospital, Jeonnam, Republic of Korea.
³Department of Biomedical Sciences, Chonnam National University Medical School, Jeonnam, Republic of Korea.
⁴Department of Biochemistry, Hanoi Medical University, Hanoi, Vietnam.
⁵CNCure Biotech, Jeonnam, Republic of Korea.
⁶Department of Microbiology and Immunology, Chonnam National University Medical School, Jeonnam, Republic of Korea.
⁷National Immunotherapy Innovation Center, Chonnam National University, Jeonnam, Republic of Korea.

^*Corresponding author: correspondence to Jung-Joon Min

Abstract

Immunotherapy has revolutionized the treatment of cancer but continues to be constrained by limited response rates, acquired resistance, toxicities and high costs, which necessitates the development of new, innovative strategies. The discovery of a connection between the human microbiota and cancer dates back 4,000 years, when local infection was observed to result in tumour eradication in some individuals. However, the true oncological relevance of the intratumoural microbiota was not recognized until the turn of the twentieth century. The intratumoural microbiota can have pivotal roles in both the pathogenesis and treatment of cancer. In particular, intratumoural bacteria can either promote or inhibit cancer growth via remodelling of the tumour microenvironment. Over the past two decades, remarkable progress has been made preclinically in engineering bacteria as agents for cancer immunotherapy; some of these bacterial products have successfully reached the clinical stages of development. In this Review, we discuss the characteristics of intratumoural bacteria and their intricate interactions with the tumour microenvironment. We also describe the many strategies used to engineer bacteria for use in the treatment of cancer, summarizing contemporary data from completed and ongoing clinical trials. The work described herein highlights the potential of bacteria to transform the landscape of cancer therapy, bridging ancient wisdom with modern scientific innovation.

논문정보

형식Review Paper
게재일2024년 06월 (BRIC 등록일 2024-06-07)
연구진국내(교신)+국외 연구진
분야 의약학 > 종양의학

댓글 작성 로그인

CV 열람하기

연락처 보기